COMMUNIQUÉS West-GlobeNewswire

Press Release Biocartis NV: Biocartis and Discovery Life Sciences Announce Strategic Collaboration to Advance Precision Oncology Diagnostics
07/07/2026
PRESS RELEASE, July 07, 2026 – 08:00 CDT Biocartis and Discovery Life Sciences Announce Strategic Collaboration to Advance Precision Oncology Diagnostics ITASCA, IL, US and HUNTSVILLE, AL, US – July 07, 2026. Today, [...]
Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation
07/07/2026
Realbotix Robots and AI to Deploy in Evidence-Based Pilot Designed to Improve Wellbeing and Address Loneliness Among Older Adults in UK Care Settings; Realbotix Becomes Accredited Supplier on Bloom’s Public Sector [...]
A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today’s Injectables Were Not Built to Fill
07/07/2026
Conexeu Completes 12-Month Preclinical P.R.O.O.F Study, Supporting Its Intended Move Into the $11 Billion Medical Aesthetics Market as a Platform¹ Study Highlights P.R.O.O.F study complete, marking an important catalyst [...]
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
07/07/2026
– Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol — – FDA agreed that a single pivotal Phase 3 trial plus confirmatory [...]
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium
07/07/2026
LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
07/07/2026
WARREN, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
07/07/2026
C1 Monoclonal Antibody Progress for RSV and Malaria Following Full $3.1 Million Gates Foundation Grant Funding JUPITER, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the [...]
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI
07/07/2026
Vancouver, Canada, July 07, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, [...]
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
07/07/2026
Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026 and late 2027, [...]
ImageneBio Appoints Matt Robbins as General Counsel
07/07/2026
Brings more than 15 years of corporate, securities, and transactional experience advising public and private life sciences companies SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene” [...]
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
07/07/2026
Novo Nordisk will conduct a non-exclusive internal evaluation of semaglutide implants prepared by Vivani ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company [...]
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
07/07/2026
WAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated [...]
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
07/07/2026
The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company [...]
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
07/07/2026
Teva-discovered TEV-’408 targets IL-15, a key driver of vitiligo biology TEV-’408 showed improvement in skin pigmentation and was well-tolerated with no safety signals observed to date Nearly 75% of patients reported [...]
Aclarion Announces Texas Spine Care Center as New CLARITY Site
07/07/2026
Texas Spine Care Center is a high-volume orthopedic spine practice with a philosophy of understanding the exact source of a patient's pain before recommending treatment CLARITY is a prospective, randomized clinical [...]
Endogenex Announces Full Enrollment of the ReCET Clinical Study
07/07/2026
350 Patients Enrolled Across Sites in the United States and Australia, Advancing the Path to FDA Approval of a Novel Endoscopic Treatment for Type 2 Diabetes MINNEAPOLIS, July 07, 2026 (GLOBE NEWSWIRE) -- Endogenex, a [...]
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
07/07/2026
Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions for two NDA [...]
U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
07/07/2026
FDA’s PDUFA goal date is November 1, 2026 If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Agios [...]
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
07/07/2026
NEWTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers [...]

Pages